Premium
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas‐Mexican border
Author(s) -
CARDENAS V. M.,
GRAHAM D. Y.,
ELZIMAITY H. M. T.,
OPEKUN A. R.,
CAMPOS A.,
CHAVEZ A.,
GUERRERO L.
Publication year - 2006
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.2006.02755.x
Subject(s) - clarithromycin , rabeprazole , amoxicillin , medicine , helicobacter pylori , urea breath test , breath test , adverse effect , population , gastroenterology , proton pump inhibitor , antibiotics , surgery , helicobacter pylori infection , microbiology and biotechnology , biology , environmental health
Summary Background Antibiotic resistance and duration of therapy influence the success of proton‐pump inhibitor‐containing Helicobacter pylori eradication therapy. Clarithromycin resistance is associated with treatment failure. Aim To examine the success of a 7‐day rabeprazole‐clarithromycin‐amoxicillin therapy in the study population. Methods Adults from Ciudad Juarez with H. pylori infections identified by culture or histology received rabeprazole 20 mg, clarithromycin 0.5 g and amoxicillin 1 g, each b.d. for 7 days. Outcome was assessed by 13 C‐urea breath test carried out 4+ weeks after treatment. Results A total of 111 patients were enrolled and evaluated by urea breath test; 102 completed the full 7 days therapy. Two deviated from protocol, and five stopped because of adverse events. The cure rate (intention‐to‐treat) was 85% (95% CI: 78–91%); the per‐protocol cure rate was 85% (95% CI: 78–91%). Side‐effects were not serious and only 6.6% of those with adverse events stopped medication. Only three isolates were clarithromycin‐resistant and none was cured. Compliance explained most of the successes. Conclusions In the study population a 7‐day rabeprazole triple eradication therapy was both effective and well‐tolerated. Clarithromycin resistance was uncommon. We observed a slightly better outcome but consistent with results from recent large studies in US populations.